Influenza produces an estimated one billion cases worldwide each year. Three to five million of those cases become severe. The statistics below detail symptom frequency, transmission patterns, mortality rates, and prevention outcomes.
Key Takeaways
- Influenza causes fever in 80-90% of symptomatic cases.
- During the 2022-2023 influenza season in the United States, the CDC estimated 31 million flu illnesses, 360,000 hospitalizations, and 21,000 flu deaths.
- Global flu deaths 290,000–650,000 annually respiratory.
- Annual flu vaccine 40-60% effective against infection.
- Influenza virus spreads via droplets within 1-2 meters.
- Oseltamivir shortens illness by 0.5-1 day.
Influenza activity is rising, highlighting the need to get vaccinated and take preventive measures now.
Related reading
01 · Category
Clinical Aspects27 stats
01
Influenza causes fever in 80-90% of symptomatic cases.
02
Cough is present in 90-98% of influenza patients.
03
Myalgias occur in 60-80% of adults with influenza.
04
Headache reported in 70-90% of influenza cases.
05
Sore throat in 50-80% of patients.
06
Fatigue lasts 2-3 weeks in 30% of cases post-influenza.
07
Rhinorrhea more common in children (60%) than adults (30%).
08
Incubation period averages 2 days (range 1-4 days).
09
Viral shedding peaks day 1, lasts 5-7 days in adults.
10
Children shed virus 7-10 days, longer if immunocompromised.
11
Pneumonia complicates 2-5% of hospitalized adults.
12
Myocarditis in 0.4-4% of fatal influenza cases.
13
Encephalitis rare, 0.2-2 per million influenza cases.
14
Acute respiratory distress syndrome (ARDS) in 10-20% severe cases.
15
Otitis media in 30-50% of children with influenza.
16
Febrile seizures in 20-30% of influenza A cases in young children.
17
Reye syndrome associated with aspirin use, now <1 case/year.
18
Lymphopenia (<1000/mm3) in 30-50% hospitalized patients.
19
Elevated CRP (>50 mg/L) in 80% of confirmed cases.
20
Procalcitonin >0.25 mcg/L suggests bacterial co-infection in 20%.
21
Thrombocytopenia (<150,000) in 10-20% severe cases.
22
Dyspnea in 40% of adults seeking care.
23
Anosmia/hyposmia in 15-30% of influenza cases.
24
Conjunctivitis in 10-20% of cases.
25
Hoarseness in 30% of patients.
26
Chest pain in 10-15% hospitalized adults.
27
Diarrhea in 10-20% of children, 5% adults.
Interpretation
Clinical Aspects Interpretation
Influenza, far more than "just a bad cold," is a master of misery that reliably brings a choir of coughs and a symphony of aches, but reserves its true virtuosity for severe complications that remind us why this annual virus demands serious respect.
02 · Category
Epidemiology30 stats
01
During the 2022-2023 influenza season in the United States, the CDC estimated 31 million flu illnesses, 360,000 hospitalizations, and 21,000 flu deaths.
02
Globally, influenza causes an estimated 1 billion cases annually, including 3-5 million severe cases.
03
In the US, influenza results in an average of 34.8 million illnesses, 16 million medical visits, 450,000 hospitalizations, and 41,000 deaths per year from 2010-2023.
04
The 2009 H1N1 pandemic caused an estimated 151,700 to 575,400 flu-related respiratory deaths worldwide.
05
In Europe, during the 2018-2019 season, WHO reported 72,000 excess deaths attributable to influenza.
06
Australia's 2019 flu season saw 313,400 laboratory-confirmed cases, a record high.
07
In the UK, influenza and pneumonia accounted for 29,516 deaths in 2022.
08
India's influenza surveillance from 2016-2021 detected influenza in 12-20% of acute respiratory illness cases.
09
Brazil reported 25,692 influenza deaths in 2020, mostly due to A(H1N1)pdm09.
10
In Japan, the 2018-2019 season had 14.5 million influenza cases.
11
China's national influenza surveillance (2017-2022) showed A(H3N2) dominating 45% of cases.
12
South Africa's 2019 sentinel surveillance detected influenza positivity in 8.5% of patients.
13
Canada estimated 12,200 flu hospitalizations in 2022-2023.
14
In the EU/EEA, 2016-2017 season had up to 170,000 influenza-associated excess deaths.
15
Mexico's 2022-2023 season reported 1,200 influenza deaths.
16
Influenza accounts for 5-10% of all pneumonia cases globally.
17
In the US, children under 5 experience 20% of flu hospitalizations.
18
Elderly over 65 represent 70-85% of flu deaths in the US annually.
19
Pregnant women have 4-8 times higher hospitalization risk from flu.
20
Indigenous populations in Australia have 5 times higher flu hospitalization rates.
21
In the US, 2009 H1N1 caused 43-89 thousand deaths.
22
Global influenza surveillance detects 100,000+ samples yearly via GISRS.
23
Influenza A(H1N1)pdm09 circulates at 20-30% positivity in recent seasons.
24
H3N2 causes longer illness duration and higher hospitalization in elderly.
25
B/Victoria lineage dominated 40% of cases in 2023 Northern Hemisphere.
26
In Africa, influenza positivity rates average 10-15% in SARI cases.
27
Russia's 2022-2023 season had 25 million cases reported.
28
In the US, flu peaks between December and February in 90% of seasons.
29
Southeast Asia sees year-round influenza with two peaks.
30
In 1918 pandemic, global deaths estimated at 50 million.
Interpretation
Epidemiology Interpretation
These global statistics, ranging from a billion annual cases to tens of thousands of tragic but preventable deaths, collectively paint influenza not as a mere seasonal nuisance but as a persistently formidable and democratic scourge, reminding us that the common flu is anything but common in its consequences.
03 · Category
Mortality19 stats
01
Global flu deaths 290,000–650,000 annually respiratory.
02
US average 34,000 flu deaths per year (2010-2020).
03
2017-2018 US season: 61,000 deaths.
04
Children <5: 100-200 US flu deaths yearly.
05
>65yo: 70-90% of US flu deaths.
06
Cardiovascular deaths from flu: 2x pneumonia deaths.
07
Pregnant women mortality risk 7x higher.
08
Obesity BMI>40: 2-3x mortality risk.
09
1918 pandemic: 675,000 US deaths.
10
1957 Asian flu: 1.1 million global deaths.
11
1968 Hong Kong flu: 1 million global deaths.
12
2009 H1N1: 12,469 lab-confirmed US deaths.
13
H5N1 avian: 455 human cases, 52% CFR (1997-2023).
14
Economic cost US: $11 billion/year healthcare.
15
Lost productivity: $60-100 billion/year US.
16
Global DALYs from flu: 16.3 million yearly.
17
ICU admission mortality 17% adults.
18
Bacterial pneumonia causes 20-40% excess flu deaths.
19
Underreporting: flu deaths 10-52x pneumonia-coded.
Interpretation
Mortality Interpretation
The flu presents itself as an annual nuisance, yet it operates with the grim efficiency of a serial killer, disproportionately targeting the old, the young, the pregnant, and the sick while quietly amassing a staggering body count and economic toll that rivals some wars.
More related reading
04 · Category
Prevention23 stats
01
Annual flu vaccine 40-60% effective against infection.
02
High-dose vaccine in >65yo: 24% efficacy vs hospitalization.
03
Vaccination prevents 11,000 US deaths yearly.
04
Coverage in US children: 60% by season end.
05
Elderly coverage: 70% in recent years.
06
Vaccine reduces GP visits by 50-60%.
07
Live attenuated vaccine 80% effective in children 2-17yo.
08
Adjuvanted vaccine 50% better in frail elderly.
09
Universal vaccine trials show 20-40% heterologous protection.
10
Antiviral prophylaxis 70-90% effective post-exposure.
11
School closures reduce spread by 20-30%.
12
Handwashing + sanitizer: 20% reduction transmission.
13
Face masks in community: 10-20% risk reduction.
14
Travel restrictions delay outbreaks by 1-2 weeks.
15
Neuraminidase inhibitors prophylaxis 79% effective.
16
Herd immunity threshold ~60-70% for seasonal flu.
17
Egg-based vaccines mismatch 10-20% due to adaptation.
18
mRNA flu vaccines phase 3 trials show 75% efficacy.
19
Nasal spray vaccine safe in egg-allergic children.
20
Annual revaccination needed due to drift.
21
Oseltamivir prophylaxis 89% in households.
22
Zanamivir 96% prophylaxis efficacy.
23
Baloxavir single dose 90% prophylaxis.
Interpretation
Prevention Interpretation
The flu vaccine is a patchwork shield—sometimes it's a robust fortress for kids and a life-saving barrier preventing thousands of deaths, while for the elderly it's more of a sturdy but leaky umbrella, yet we keep sewing on new layers each year because even imperfect armor is far better than going into battle naked.
05 · Category
Transmission25 stats
01
Influenza virus spreads via droplets within 1-2 meters.
02
Aerosol transmission possible in poorly ventilated spaces.
03
Infectious period 1 day before to 5-7 days after symptom onset.
04
Children shed higher viral loads, longer periods.
05
Surface fomites viable up to 48 hours on hard surfaces.
06
Virus survives 24 hours on porous surfaces.
07
R0 for seasonal flu 1.3 (range 1.2-1.4).
08
H1N1pdm09 R0 estimated at 1.5.
09
Household secondary attack rate 10-38%.
10
School settings have 14-40% attack rates.
11
Nosocomial transmission in 1-5% of hospitalized patients.
12
Hand hygiene reduces transmission by 16-21%.
13
Masks reduce risk by 70-80% in household contacts.
14
Social distancing >1m lowers risk by 82%.
15
Ventilation reduces airborne transmission by 30-70%.
16
Animal reservoirs include pigs (triple reassortant), birds (H5N1).
17
Human-to-human sustained for novel strains rare without adaptation.
18
Superspreading events contribute 10-20% transmissions.
19
Asymptomatic shed virus in 30-50% cases.
20
Pre-symptomatic transmission 40-60% of cases.
21
Contact tracing identifies 20-30% secondary cases.
22
Public transport high risk, attack rate 5-10%.
23
Cold weather increases survival, transmission peaks winter.
24
Humidity <20% optimal for aerosol stability.
25
UV light inactivates virus in minutes.
Interpretation
Transmission Interpretation
The flu is a crafty, airborne menace that thrives in our winter breath, spreads before we even feel sick, and is foiled by the simple, heroic acts of handwashing, masking, and giving each other a little space.
06 · Category
Treatment19 stats
01
Oseltamivir shortens illness by 0.5-1 day.
02
Within 48 hours, antivirals reduce complications by 50%.
03
Hospitalized patients: oseltamivir reduces mortality 25%.
04
Baloxavir faster viral clearance than oseltamivir.
05
Zanamivir safe alternative for oseltamivir-resistant cases.
06
Peramivir IV for critically ill, reduces ICU stay.
07
Supportive care: hydration, antipyretics standard.
08
Avoid salicylates in children to prevent Reye.
09
Antibiotics only for bacterial superinfection (10-20% cases).
10
ECMO survival 60% in severe pediatric H1N1.
11
Steroids not recommended routinely, increase mortality.
12
Remdesivir in vitro active, limited clinical benefit.
13
Favipiravir phase 3 showed no benefit over oseltamivir.
14
Recovery median 7 days in uncomplicated cases.
15
Resistance to oseltamivir 0.5-2% seasonal H1N1.
16
H3N2 resistance low (<1%).
17
Post-exposure prophylaxis 75-90% effective.
18
Outpatient antivirals reduce hospitalization 40% high-risk.
19
ICU mortality 20-30% in severe influenza.
Interpretation
Treatment Interpretation
While antivirals offer a modest head start in the race against the flu clock—shaving off half a day, cutting complications, and saving lives in a pinch—their true power is a conditional shield, best deployed early and strategically within a broader battle plan of supportive care and sober respect for the virus's lethal potential.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Influenza Statistics. Gitnux. https://gitnux.org/influenza-statistics
MLA
Diana Reeves. "Influenza Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/influenza-statistics.
Chicago
Diana Reeves. 2026. "Influenza Statistics." Gitnux. https://gitnux.org/influenza-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level